Your browser doesn't support javascript.
loading
Performance of [18F]fluorocholine PET/CT in MEN1-related primary hyperparathyroidism before initial surgery or for persistent/recurrent disease.
Boucher, Aymeric; Delabie, Julia; Lussey-Lepoutre, Charlotte; Haissaguerre, Magalie; Ouvrard, Eric; Lavinia, Vija; Le Bras, Maëlle; Batisse-Lignier, Marie; Cuny, Thomas; Jacquet-Francillon, Nicolas; Gaujoux, Sébastien; Molina, Océane; Imperiale, Alessio; Latge, Adrien; Ansquer, Catherine; Kelly, Antony; Borson-Chazot, Françoise; Tlili, Ghoufrane; Sebag, Frédéric; Hamidou, Zeinab; Romanet, Pauline; Taïeb, David.
Afiliación
  • Boucher A; Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, 264 Rue Saint-Pierre, 13385, Marseille, France.
  • Delabie J; Department of Endocrinology, Hôpital Louis Pradel, Hospices Civils de Lyon and Claude Bernard Lyon 1 University, Lyon, France.
  • Lussey-Lepoutre C; Department of nuclear medicine, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France.
  • Haissaguerre M; Department of Endocrinology and Endocrine Oncology, Haut Leveque Hospital, University Hospital of Bordeaux, Pessac, France.
  • Ouvrard E; Department of Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe (ICANS), Strasbourg, France.
  • Lavinia V; Department of Nuclear Medicine, Oncopole Claudius Regaud, Toulouse, France.
  • Le Bras M; Department of Endocrinology, Diabetology and Nutrition, L'institut du Thorax, CHU Nantes, 44000, Nantes, France.
  • Batisse-Lignier M; Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.
  • Cuny T; Department of Endocrinology, Conception Hospital, Aix-Marseille University, Marseille, France.
  • Jacquet-Francillon N; Department of Nuclear Medicine, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon Sud Hospital, Pierre-Bénite, Lyon, France.
  • Gaujoux S; Department of General, Visceral, and Endocrine Surgery, Pitié-Salpêtrière Hospital, AP-HP, Paris Sorbonne Université, Paris, France.
  • Molina O; Department of Endocrinology and Endocrine Oncology, Haut Leveque Hospital, University Hospital of Bordeaux, Pessac, France.
  • Imperiale A; Department of Nuclear Medicine and Molecular Imaging, Institut de Cancérologie de Strasbourg Europe (ICANS), Strasbourg, France.
  • Latge A; Department of Nuclear Medicine, Oncopole Claudius Regaud, Toulouse, France.
  • Ansquer C; Department of Nuclear Medicine, CHU Nantes, Nantes Université, 44000, Nantes, France.
  • Kelly A; Department of Nuclear Medicine, Centre Jean Perrin, Clermont-Ferrand, France.
  • Borson-Chazot F; Department of Endocrinology, Hôpital Louis Pradel, Hospices Civils de Lyon and Claude Bernard Lyon 1 University, Lyon, France.
  • Tlili G; Department of Nuclear Medicine, Bordeaux University and Hospitals, 33604, Bordeaux, France.
  • Sebag F; Department of Endocrine Surgery, Aix-Marseille University, Conception Hospital, Marseille, France.
  • Hamidou Z; Department of Public Health, Aix-Marseille University, Marseille, France.
  • Romanet P; Laboratory of Molecular Biology Hospital La Timone, Aix Marseille Univ, APHM, INSERM, MMG, Marseille, France.
  • Taïeb D; Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, 264 Rue Saint-Pierre, 13385, Marseille, France. david.taieb@ap-hm.fr.
Eur J Nucl Med Mol Imaging ; 51(5): 1349-1360, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38057652
ABSTRACT

PURPOSE:

The aims of the study were to evaluate the performance and robustness of [18F]fluorocholine PET/CT in detecting hyperfunctioning parathyroid glands in MEN1-related primary hyperparathyroidism (pHPT) at different stages of their disease.

METHODS:

Retrospective French multicenter study including patients with MEN1 pHPT who underwent [18F]fluorocholine PET/CT at initial diagnosis or for evaluation of persistent/recurrent disease. PET/CT were independently reviewed by two readers in a blinded manner. The assessment of PET/CT on a per-patient basis was assessed using a comprehensive set of criteria that considered pathological findings or agreement with alternative diagnostic methods in non-operated patients. The secondary objectives included the analysis of the performance of PET/CT at a per-lesion level, with reference to a pathological Gold Standard, and examining its interobserver reproducibility.

RESULTS:

A total of 71 MEN1 patients were included (73 PET/CT) in the study. At the per-patient level (entire cohort), [18F]fluorocholine PET/CT sensitivity ranged from 98.5 to 100% among the different readers. An average of 1.77 glands per PET was described, with 2.35 glands at the initial diagnosis (n = 23) and 1.5 in previously operated cases (n = 50). PET/CT detected more lesions than conventional imaging work-up (neck ultrasound and/or scintigraphy). At the per-lesion level (41 operated patients), sensitivity ranged across different readers from 84.4 to 87%, and specificity ranged from 94.7 to 98.8%. At initial diagnosis, all patients that exhibited 3 or more abnormal glands on PET underwent subtotal parathyroidectomy while 7 out of 13 patients with 1 or 2 gland abnormalities on PET underwent less than subtotal parathyroidectomy. Finally, the degree of inter-observer agreement was high.

CONCLUSION:

[18F]fluorocholine PET/CT is a reliable and robust imaging modality for the evaluation of MEN1-related pHPT and could guide surgeons in achieving the optimal benefit-risk ratio. This study gives a great impetus for its adoption as a primary diagnostic tool in this context.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Colina / Hiperparatiroidismo Primario / Tomografía Computarizada por Tomografía de Emisión de Positrones Límite: Humans Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Colina / Hiperparatiroidismo Primario / Tomografía Computarizada por Tomografía de Emisión de Positrones Límite: Humans Idioma: En Revista: Eur J Nucl Med Mol Imaging Asunto de la revista: MEDICINA NUCLEAR Año: 2024 Tipo del documento: Article País de afiliación: Francia